Aprotinin in the management of life-threatening bleeding during extracorporeal life support.
Contact with the synthetic surfaces of an extracorporeal circuit induces alterations in vascular components, derangements of the coagulation cascade and a systemic inflammatory response. Aprotinin reduces intraoperative and postoperative bleeding in adults undergoing cardiopulmonary bypass; however, trials in children have not had similar favorable results. While there have been some anecdotal reports, there have been no prospective clinical trials exploring the utility of aprotinin in the prevention of or as a therapy for bleeding while on extracorporeal life support (ECLS). We present a case series on our experience utilizing aprotinin for the treatment of life-threatening bleeding during ECLS. The combination of a loading dose followed by a continuous infusion resulted in significant reduction in blood loss and blood product utilization. This suggests that aprotinin may have clinical efficacy in the management of massive blood loss while on ECLS; however, larger controlled trials will be essential to determine the efficacy and appropriate dosing regimens before widespread use in ECLS can be advocated.
Biswas
A K
AK
Department of Pediatrics, Children's Medical Center of Dallas and the University of Texas Southwestern Medical Center, USA. akbiswas@pnh10.med.navy.mil
Lewis
L
L
Sommerauer
J F
JF
D000293:Adolescent; D007611:Aprotinin / Q000008:administration & dosage* / Q000592:standards; D001672:Biocompatible Materials / Q000009:adverse effects; D002648:Child; D016638:Critical Illness; D005112:Extracorporeal Circulation / Q000009:adverse effects*; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007263:Infusions, Parenteral; D008297:Male; D051437:Renal Insufficiency / Q000209:etiology / Q000503:physiopathology
D001672:Biocompatible Materials; D007611:Aprotinin